Key Events This Week
22 Jun: New 52-week high (Rs.705)
23 Jun: Strong technical momentum with 19.7% intraday surge
24 Jun: New 52-week high of Rs.740 amid sector outperformance
25 Jun: Week closes at Rs.709.55 (+0.93%)

Broad-Based Technical Strength Lifts Shree Ganesh Remedies Ltd to 52-Week High of Rs 740
2026-06-24 13:41:17Surging to an intraday peak of Rs 740 on 24 Jun 2026, Shree Ganesh Remedies Ltd has marked a significant milestone by reaching a fresh 52-week high. This achievement comes amid a backdrop of strong technical momentum and sustained outperformance relative to its sector and the broader market.
Read full news article
Shree Ganesh Remedies Ltd is Rated Hold
2026-06-23 10:10:04Shree Ganesh Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.
Read full news article
Broad-Based Technical Strength Lifts Shree Ganesh Remedies Ltd to 52-Week High of Rs 705
2026-06-22 09:59:49With a climb to Rs 705 on 22 Jun 2026, Shree Ganesh Remedies Ltd has reached a fresh 52-week high, marking a notable 85% rally from its low of Rs 381.1 over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained upward price trends, even as the stock experienced a mild pullback today.
Read full news article
Shree Ganesh Remedies Ltd Sees Strong Technical Momentum Amid Market Outperformance
2026-06-22 08:03:13Shree Ganesh Remedies Ltd has demonstrated a significant shift in price momentum, supported by a range of bullish technical indicators. The pharmaceutical and biotechnology company’s shares surged 19.69% in a single day, closing at ₹703.00, just shy of its 52-week high of ₹704.80. This price action, coupled with improved technical parameters, has prompted an upgrade in its MarketsMOJO grade from Sell to Hold, reflecting growing investor confidence amid a micro-cap valuation.
Read full news article









